.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Novartis
Fuji
Healthtrust
Mallinckrodt
Dow
Chinese Patent Office
Medtronic
QuintilesIMS
Merck

Generated: July 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,779,468

« Back to Dashboard

Which drugs does patent 6,779,468 protect, and when does it expire?


Patent 6,779,468 protects TRIFERIC and is included in one NDA.

This patent has twenty-four patent family members in eighteen countries.

Summary for Patent: 6,779,468

Title: Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
Abstract:A method of administering iron to dialysis patients is accomplished by infusion of a noncolloidal ferric compound, soluble in hemodialysis or peritoneal dialysis solutions, by the process of dialysis. A pharmaceutical composition is provided consisting essentially of dialysis solution including a soluble noncolloidal ferric compound, preferably ferric pyrophosphate.
Inventor(s): Gupta; Ajay (Farmington Hills, MI)
Assignee:
Application Number:09/341,032
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Rockwell Medical Inc
TRIFERIC
ferric pyrophosphate citrate
SOLUTION;IV (INFUSION)206317-001Jan 23, 2015RXYesYes6,779,468► Subscribe METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,779,468

PCT Information
PCT FiledDecember 30, 1997PCT Application Number:PCT/US97/23719
PCT Publication Date:July 09, 1998PCT Publication Number: WO98/29434

Non-Orange Book Patents for Patent: 6,779,468

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,689,275 Method and pharmaceutical composition for replacing iron losses in dialysis patients► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,779,468

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Turkey9901518► Subscribe
Slovenia20151► Subscribe
Poland191377► Subscribe
Poland334437► Subscribe
New Zealand336319► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
UBS
Healthtrust
Chubb
QuintilesIMS
AstraZeneca
Colorcon
Moodys
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot